DOV Ocinaplon Phase III Anxiety Trial On Hold Again Over Liver Function Tests
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
DOV's internal review of Phase III safety data on its anxiolytic ocinaplon will take "several months" and could result in a reduced dosing regimen